Meeting
2013 ASCO Annual Meeting
Genetic and molecular biomarker characterization of KRAS mutant non-small cell lung carcinoma (NSCLC) tumors.
Authors
Li Liu
GlaxoSmithKline, Oncology, Collegeville, PA
Li Liu , Yuan Liu , Ademi Santiago-Walker , Hong Shi , Vivian Zhang , Ashley Hughes , Carmen P. Arenas-Elliott , Lori Roadcap , Anne-Marie Martin , Tona M. Gilmer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 11026)
DOI
10.1200/jco.2013.31.15_suppl.11026
Abstract #
11026
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2017 Gastrointestinal Cancers Symposium
Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
First Author: Gemma Bruera
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.
First Author: Brendon Fusco
Poster
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
First Author: Shengli Yang